Korean oral obesity, insulin stock yo-yos on rumors

Sam Chun Dang Pharm, once the top market-cap company on Korea’s Kosdaq driven by optimism over its oral insulin and obesity drug pipeline, said it has been “maliciously framed” after its stock plunged as doubts over its proprietary technology grew.